where circulating immune complexes have been demonstrated.
Immune complexes have been studied in relation to the pathogenesis of human and animal disorders including malignant diseases (Hoffken et al., 1978b; Baldwin et al., 1979; Terman et al., 1980) . In recent years sensitive techniques have been applied to detect immune complexes in sera from patients with many types of tumour (reviewed by . Circulating immune complexes in human osteosarcoma have been studied using the Clq binding test by Tsang et al. (1979) and in this laboratory by Segal-Eiras et al. (1980) .
The possibility of investigating a large population of dogs with o.s. allowed the development of the present study, in which the incidence of sera with raised Clq binding could be determined, and a preliminary investigation of changes in Clq binding with disease progress could be made.
These investigations were performed in parallel with human bone-tumour immune-complex studies, and used human Clq, which has previously been shown to bind rat (Hoffken et al., 1978a) and dog (Terman et al., 1979) Serum samples were applied to Sepharose 4B-CL Protein A columns. Unbound protein eluted in PBS and bound fractions eluted with pH 2-8 buffer were neutralized, concentrated to the volume of the original serum sample, dialysed against PBS and tested in the 125I-Clq binding assay.
for normal dogs was established in tests of samples from 22 clinically healthy female beagles aged 2-7 years, and 12 healthy wolfhounds of both sexes with an age range of 5-7 years. Clq-binding values shown in Table I ranged from 5.5 to 12.3% (mean 855 + 2.7 %). For comparative purposes, a high value was taken to be >14.0% or mean+2 s.d. of the control serum samples. Fifty-six dogs with spontaneous osteosarcoma confirmed at biopsy or post mortem examination were studied; most were of large breed (Owen, 1969) . Forty-six out of 56 serum samples from dogs with osteosarcoma had high Clqbinding levels ranging from 14 2 to (mean 39.9+14.7%)/ Sera from dogs with either lymphosarcoma, fibrosarcoma or mammary carcinoma also had high levels in 10/10 cases; range 21-9-64*3 (mean 34.4 + 13-4). In contrast, sera from a small group of dogs with non-malignant diseases, including healing fractures, osteoarthritis, diabetes melitus, otitis externa and skin diseases, had low levels of Clq binding (1/8 positive, range 7-5-14-8, mean 112 + 30).
Experiments were performed to investigate the nature of the serum Clq binding material by determining its affinity for Protein A. Serum samples were dialysed against buffered saline (PBS pH 7.2) and applied to a 2ml column of Protein ASepharose CL4B (Pharmacia) equilibrated with the same buffer. Unbound material was eluted with PBS, and bound fractions eluted with 01M glycine HCl buffer (pH 2.8). After neutralization, serum fractions were concentrated to the original volume, dialysed against PBS and centrifuged (800 g) for 30 min before testing in the Clq-binding assay. Because of the limited quantities of sera available, these studies were performed using not only individual samples but also from a pool of sera from 3 dogs with o.s. (Table II) 
